Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs... Show more
a developer thin film pharmaceutical and over the counter drug products
Industry PharmaceuticalsGeneric
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| AASSX | 26.57 | 0.19 | +0.72% |
| American Beacon Small Cp Val Adv | |||
| RGBFX | 42.83 | 0.01 | +0.02% |
| American Funds Global Balanced R-5 | |||
| RYLVX | 142.31 | N/A | N/A |
| Rydex S&P 500 Pure Value A | |||
| JFCIX | 37.62 | N/A | N/A |
| JHancock Fundamental All Cap Core I | |||
| CCWIX | 21.82 | N/A | N/A |
| Baird Chautauqua International Gr Instl | |||
A.I.dvisor indicates that over the last year, AQST has been loosely correlated with SXTC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then SXTC could also see price increases.
| Ticker / NAME | Correlation To AQST | 1D Price Change % | ||
|---|---|---|---|---|
| AQST | 100% | -4.21% | ||
| SXTC - AQST | 45% Loosely correlated | +32.64% | ||
| HROW - AQST | 33% Loosely correlated | -5.74% | ||
| PCRX - AQST | 26% Poorly correlated | +0.79% | ||
| ACET - AQST | 26% Poorly correlated | -0.10% | ||
| CPHI - AQST | 26% Poorly correlated | -0.35% | ||
More | ||||
| Ticker / NAME | Correlation To AQST | 1D Price Change % |
|---|---|---|
| AQST | 100% | -4.21% |
| Pharmaceuticals: Generic industry (84 stocks) | 57% Loosely correlated | -0.05% |
The 10-day RSI Oscillator for AQST moved out of overbought territory on September 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 27 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.
The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AQST as a result. In 67 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
AQST broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
AQST moved above its 50-day moving average on August 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AQST crossed bullishly above the 50-day moving average on August 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +5.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in 213 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 143 of 178 cases where AQST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (46.728). P/E Ratio (0.000) is within average values for comparable stocks, (93.360). AQST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (10.627) is also within normal values, averaging (176.516).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.